Several factors have been identified as predictive biomarkers for anti-PD1/PDL1 immunotherapy response, including PD-L1 expression in tumor cells and tumor-infiltrating lymphocytes, tumor mutational burden (TMB), microsatellite instability (MSI), and/or mismatch repair deficiency (MMR) (69–71). Here, CD274 is linked to neoplasm.